Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
News|Podcasts|August 4, 2026
ACT Brief: Trial Execution Cost Burden and Protocol Variability, Real-World Oncology Data Curation Complexity, and Real-Time Analytics Datapoint Scale
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine the $500,000-per-day cost of execution delays and protocol variance at the point of care, why oncology real-world data requires hybrid clinical expertise with technology, and scaling challenges as trial data volumes continue to grow.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a
contributed article , Richard Graham, chairman and co-founder of TruTechnologies, examined how poor execution at the point of care drives most trial delays and what poor execution costs. Tufts estimates delayed market entry at approximately 500,000 dollars per day in unrealized sales, with Phase III trials costing nearly 56,000 dollars per day in direct conduct costs; multiplied across sites and phases, capture and documentation inconsistencies become material trial risks that AI discovery tools cannot fix. - In a
new contributed article , C.K. Wang, chief medical officer at Verana Health, described why real-world oncology data requires a hybrid curation approach pairing clinical expertise with technology. Complex oncology concepts like lines of therapy and treatment exposure remain implicit rather than explicit in electronic health records, requiring both advanced algorithms and clinical expert validation to ensure data plausibility and research readiness. - In an
article from Pharmaceutical Executive , Christian Schmidt examined how escalating datapoint volumes are overwhelming traditional data management. Phase III trials now generate an average of 5.9 million datapoints per protocol, up 11 percent annually since 2020, while most sponsors still manage data manually with periodic reviews weeks after collection, delaying detection of protocol deviations and adverse events.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Trending on Applied Clinical Trials Online
1
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
2
What It Takes to Harmonize AI Across Fragmented Oncology Health Systems
3
Using AI to Design Better Trials Before the First Patient Enrolls: Q&A with Claire Riches, Citeline
4
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
5